Precision Oncology Referrals: A Guide for Doctors

Precision Oncology: What Community Doctors Should Know Before Referring Patients

Introduction

Precision oncology has moved from an experimental concept to a routine part of cancer care for several common malignancies, including lung, breast, and colorectal cancers. For community doctors and general physicians who are often the first point of contact for a patient with a new cancer diagnosis, understanding when and how to refer for molecular testing has become as important as recognising the disease itself. A patient's treatment trajectory can change substantially depending on whether biomarker testing was done early, done late, or not done at all.

This is not a call for every general physician to become a molecular pathologist. It is, instead, a practical orientation to help referring doctors ask the right questions, set correct expectations with patients, and know which cases genuinely warrant a specialist referral for genomic testing versus which do not. In India, where oncology infrastructure varies significantly between metropolitan centres and smaller towns, this clarity matters even more.

Understanding the Basics of Precision Oncology

Precision oncology, sometimes called personalised oncology, refers to treatment decisions guided by the specific molecular characteristics of a patient's tumour rather than by cancer type and stage alone. Two tumours that look identical under a microscope and carry the same stage classification can behave very differently and respond to very different drugs, depending on what genetic alterations are driving their growth.

The foundation of this approach rests on identifying biomarkers, which are measurable changes in genes, proteins, or other molecules that indicate how a tumour is likely to behave or respond to treatment. Some biomarkers are well established with strong evidence and approved companion drugs, such as HER2 in breast cancer or EGFR mutations in non-small-cell lung cancer. Others remain investigational, meaning a laboratory may report the alteration, but there is not yet strong evidence connecting it to a specific effective therapy.

For a referring doctor, the key distinction to hold onto is this: not every genomic alteration reported on a test result is immediately actionable, and interpreting which ones matter requires oncology expertise. A community physician's job is generally not to interpret these reports directly but to recognise which patients are good candidates for this pathway and to refer them at the right time.

Which Patients Are Good Candidates for Referral

Several clinical situations make a strong case for early referral to a medical oncologist for consideration of molecular testing.

Patients with metastatic or advanced disease at diagnosis are usually the clearest candidates, particularly in cancers such as non-small-cell lung cancer, where testing for EGFR, ALK, ROS1, and PD-L1 status now routinely shapes the first treatment decision rather than being an afterthought. Metastatic colorectal cancer is another example, where RAS and BRAF status inform whether certain antibody therapies will help or should be avoided entirely.

Patients whose cancer has progressed after standard treatment options are also strong candidates, particularly when no further standard therapy line exists. In these situations, broader panel testing may reveal a rare but targetable alteration that opens access to a clinical trial or an approved drug being used outside its original indication.

Patients with rare cancers or unusual presentations, where standard treatment guidance is limited, may also benefit from early referral, since basket trials increasingly enrol patients based on the mutation present rather than the organ of origin.

On the other hand, most patients with early stage, localised cancer undergoing treatment with curative intent generally do not need broad genomic panels. Standard pathology markers already used for decades, such as hormone receptor and HER2 status in early breast cancer, remain the relevant tests in this setting. Referring every early stage patient for expensive panel testing they are unlikely to need can create financial strain without changing management.

Recognising When Testing Timing Matters

Timing of biomarker testing affects both clinical outcomes and the patient's experience of care. For a patient newly diagnosed with metastatic lung cancer, waiting for comprehensive testing results before starting treatment can feel difficult, since most patients want to begin fighting the disease immediately. However, starting an ill suited treatment before results return can mean losing time on a therapy unlikely to work, when a matched option might have been available with a short wait.

Community doctors play an important role here by preparing patients for this reality at the time of referral, explaining that a wait of one to four weeks for full test results is often expected, and that this wait is generally worthwhile. Setting this expectation early reduces anxiety and prevents patients from pressuring treating oncologists into premature treatment starts.

Rebiopsy decisions are another area where timing matters. When a patient's cancer has been responding to a targeted drug but then begins progressing, this often signals that the tumour has developed a resistance mutation. A referral back to the treating oncologist at this point, rather than assuming the original treatment plan should simply continue, can open the door to second generation targeted drugs designed specifically for these resistance patterns.

Diagnosis and the Testing Process Explained Simply

For doctors who want to explain the process to worried patients and families without getting into excessive technical depth, a few core concepts are useful to convey.

Testing can be done on tumour tissue obtained through biopsy or surgery, or increasingly through a blood sample known as a liquid biopsy, which looks for tumour DNA circulating in the bloodstream. Liquid biopsy is particularly useful when a tissue biopsy would be risky or when the tumour is difficult to reach, though a negative liquid biopsy result may still require a follow-up tissue sample if no biomarkers are detected. The two methods are complementary rather than fully interchangeable.

The laboratory sequencing itself can range from testing a small set of well known genes to testing several hundred genes at once, depending on the clinical situation and the specific panel ordered. Sequencing depth and quality vary between laboratories, and there is currently no single national standard governing these tests, so working with an established, accredited laboratory matters.

Once results are available, a molecular tumour board, where oncologists, pathologists, and sometimes genetic counsellors review results together, often provides the most reliable interpretation, particularly for less common alterations. Community doctors should feel comfortable telling patients that this multidisciplinary review is a normal and valuable part of the process rather than a delay.

Some patients will also benefit from separate genetic testing, distinct from tumour biomarker testing, particularly when there is a strong family history of cancer or when the biomarker found in the tumour, such as a BRCA mutation, could also represent an inherited risk relevant to other family members. This distinction between testing the tumour's genes and testing the patient's own inherited genes is often confusing for patients and worth explaining clearly during the referral conversation.

Treatment Implications and What Referring Doctors Should Communicate

Once biomarker results guide a treatment plan, patients frequently have questions that their referring physician, as a trusted first contact, may need to help address even after the oncology team has taken over primary treatment decisions.

A few points are worth communicating clearly to patients before and during this process:

• A positive biomarker result does not guarantee a treatment will work indefinitely; tumours can develop resistance over time, and ongoing monitoring remains part of the treatment plan.
• Targeted therapies generally cause different side effects than traditional chemotherapy, and patients should not assume the experience will be identical to what they may have heard from others treated with older regimens.
• Access to certain targeted drugs may depend on clinical trial availability, insurance coverage, or approval status in India, and these practical factors are worth discussing early rather than after testing is complete.

Community doctors are also well placed to reinforce that a negative or inconclusive biomarker result is not a treatment failure. It simply means that, for that particular patient, standard treatment approaches remain the appropriate path, and this outcome is common rather than unusual.

The Indian Context: Access, Cost, and Growing Infrastructure

India's precision oncology landscape has expanded considerably over the past decade, though access remains uneven. Comprehensive genomic testing and next-generation sequencing panels are increasingly available at major cancer centres in metropolitan cities, but tier 2 and tier 3 cities often still depend on sending samples to centralised laboratories, which can extend turnaround times.

Cost remains a significant factor in patient decision-making. While the price of sequencing technology has fallen substantially worldwide, comprehensive panel testing in India can still represent a meaningful expense for many families, and insurance coverage for these tests varies by policy and provider. Government schemes such as Ayushman Bharat have expanded access to cancer treatment broadly, though coverage specifically for advanced molecular diagnostics continues to evolve. Community doctors making referrals should set realistic expectations about cost early in the conversation rather than leaving patients to discover this only at the testing stage.

India's cancer burden also shapes which biomarkers are most relevant in daily practice. Lung cancer, breast cancer, and colorectal cancer represent a substantial share of the biomarker-driven referral cases seen in Indian oncology practice, and EGFR mutation rates in Indian and broader Asian lung cancer populations tend to be higher than in Western populations, making testing for this marker particularly relevant when referring lung cancer patients in India.

The National Medical Commission and professional oncology bodies in India continue to publish and update guidance on when biomarker testing is indicated, and staying familiar with these evolving recommendations, alongside international guidelines from bodies such as the National Comprehensive Cancer Network, helps referring doctors make sound, current decisions.

Building Stronger Referral Pathways Between Community Doctors and Oncology Teams

Precision oncology works best when there is genuine two-way communication between the referring physician and the treating oncology team. A community doctor who understands enough about biomarker testing to explain the process, set expectations, and answer basic patient questions becomes a far more effective partner in the care pathway than one who refers a patient and steps entirely out of the conversation.

Platforms that connect doctors with oncology specialists and give physicians a space to discuss clinical questions, share case experiences, and stay updated on evolving practice patterns can meaningfully strengthen these referral relationships. HealthVoice exists to support exactly this kind of professional connection, giving doctors and healthcare associations a credible space to exchange knowledge, discuss clinical developments such as advances in precision oncology, and build the kind of collaborative relationships that ultimately benefit patient care.

Continuing medical education focused specifically on biomarker driven treatment, whether through association led events, hospital tumour boards, or professional community discussions, remains one of the most effective ways for community doctors to stay current in a field that is evolving quickly.

Conclusion

Precision oncology has fundamentally changed how many common cancers are treated, but its value depends heavily on timely and appropriate referral from the doctors who see patients first. Community physicians do not need to master molecular pathology to play their part effectively. What matters most is recognising which patients are strong candidates for biomarker testing, understanding that timing affects outcomes, communicating honestly with patients about what testing can and cannot promise, and maintaining an open line of communication with oncology specialists throughout the patient's journey. As testing becomes more accessible across Indian cities and more biomarkers gain clinical relevance, this referral judgment will only grow more important to good cancer care.

Frequently Asked Questions

Q1: When should a community doctor refer a patient for precision oncology testing?

Referral is generally appropriate for patients with metastatic or advanced disease, particularly non small cell lung cancer, once a tissue diagnosis is confirmed and before first line treatment decisions are finalised, since several biomarkers now guide first line therapy choice.

Q2: Is biomarker testing required for early stage cancers?

In most early stage cancers undergoing curative treatment, broad genomic panels are not required. Standard markers such as hormone receptors and HER2 in early breast cancer remain the relevant tests, and broader testing is generally reserved for advanced or recurrent disease.

Q3: What is the difference between biomarker testing and genetic testing?

Biomarker testing examines the tumour's own genetic material to identify mutations driving its growth, while genetic testing examines the patient's inherited DNA to identify hereditary cancer risk. Both may be relevant for the same patient but answer different clinical questions.

Q4: Is precision oncology testing affordable and accessible in India?

Cost and access have improved but remain uneven across India. Tier 1 cities generally have better laboratory access than tier 2 and tier 3 cities, and insurance coverage for testing varies, so discussing cost expectations with patients and families early is important.

Q5: Should every patient with actionable mutations receive targeted therapy immediately?

Not necessarily. Many detected alterations are classified as variants of unknown significance or lack strong clinical evidence for a specific drug pairing. Referral to a molecular tumour board or oncologist experienced in interpreting these reports is advisable before acting on results.

#PrecisionOncology #CancerCare